PPI-100 is an immune‑reprogramming therapeutic that mobilizes innate immunity to treat cancers and infectious diseases, targeting perioperative oncology to reduce post‑surgical relapse. Built on a predecessor with proven ex‑US clinical use and de‑risking dose‑escalation safety and PD data, PPI-100 offers improved efficacy/safety and robust IP while advancing toward clinical studies.